Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference
September 08 2022 - 7:00AM
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical
company focused on developing novel synthetic lethality-based
cancer therapeutics targeting DNA damage response (DDR) pathways,
today announced that Oren Gilad Ph.D, President and Chief Executive
Officer, will present a corporate overview at the H.C. Wainwright
24th Annual Global Investment Conference on Monday, September 12,
2022 at 12:30 p.m. ET.
The presentation will discuss Aprea’s discovery program and
development pipeline in synthetic lethality and DDR, including:
- ATRN-119, the
Company’s Phase 1-ready small molecule ATR inhibitor
- ATRN-W1051, the
Company’s WEE1 inhibitor in preclinical development
- Repli-Biom, the
Company’s discovery platform to identify both new precision
oncology targets and patient populations most likely to benefit
from treatment
- Eprenetapopt, the
Company’s clinical-stage small molecule p53 reactivator
A copy of the presentation will be accessible from the “Events
Calendar” in the News and Events section of the Aprea website.
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical company
headquartered in Boston, Massachusetts with research facilities in
Doylestown, Pennsylvania, focused on developing novel synthetic
lethality-based cancer therapeutics targeting DNA damage response
pathways. The Company’s lead program is ATRN-119, a Phase 1-ready
small molecule ATR inhibitor being developed for solid tumor
indications. ATRN-W1051, the Company’s novel WEE1 inhibitor, is in
preclinical development. For more information, please visit the
company website at www.aprea.com.
The Company may use, and intends to use, its investor relations
website at https://ir.aprea.com/ as a means of disclosing material
nonpublic information and for complying with its disclosure
obligations under Regulation FD.
Forward Looking Statement
Certain information contained in this press release includes
“forward-looking statements”, within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, related to our study
analyses, clinical trials, regulatory submissions, and projected
cash position. We may, in some cases use terms such as “future,”
“predicts,” “believes,” “potential,” “continue,” “anticipates,”
“estimates,” “expects,” “plans,” “intends,” “targeting,”
“confidence,” “may,” “could,” “might,” “likely,” “will,” “should”
or other words that convey uncertainty of the future events or
outcomes to identify these forward-looking statements. Our
forward-looking statements are based on current beliefs and
expectations of our management team that involve risks, potential
changes in circumstances, assumptions, and uncertainties. Any or
all of the forward-looking statements may turn out to be wrong or
be affected by inaccurate assumptions we might make or by known or
unknown risks and uncertainties. These forward-looking statements
are subject to risks and uncertainties including risks related to
the success and timing of our clinical trials or other studies,
risks associated with the coronavirus pandemic and the other risks
set forth in our filings with the U.S. Securities and Exchange
Commission. For all these reasons, actual results and developments
could be materially different from those expressed in or implied by
our forward-looking statements. You are cautioned not to place
undue reliance on these forward-looking statements, which are made
only as of the date of this press release. We undertake no
obligation to publicly update such forward-looking statements to
reflect subsequent events or circumstances.
Source: Aprea Therapeutics, Inc.
Corporate Contacts:
Scott M. CoianteSr. Vice President and Chief Financial
Officer617-463-9385
Gregory A. KorbelSr. Vice President and Chief Operating
Officer617-463-9385
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jul 2023 to Jul 2024